FDA approves GSK’s Hibsago as first functional cure for hepatitis B
The FDA approved GSK's Hibsago (bepirovirsen) as the first functional cure for hepatitis B in the US. The drug is for patients without cirrhosis, already on NRTI therapy, with suppressed HBV DNA and low HBsAg levels. GSK expects peak annual sales of over $2.68bn. The drug showed a 19% functional cure rate in trials, with manageable safety warnings. GSK aims for $40bn+ in annual revenue by 2031, with Hibsago as a key driver.
How this was made
The 30-second read
Why it matters
The approval unlocks a new revenue stream projected at >£2bn annually, supporting GSK's target of £40bn revenue by 2031.
Market read
A major regulatory win for a large pharma firm, likely to move the stock and influence the broader healthcare sector.
What to watch
Pricing, reimbursement negotiations, and competition from existing HBV therapies may affect actual sales.
Background
GSK's Hibsago (bepirovirsen) received FDA approval, marking the first functional cure for hepatitis B in the U.S. after prior approval in Japan.
Ticker impact
FDA approval of Hibsago as the first functional cure for hepatitis B, a new product launch for GSK.
likely upward pressure as the market prices in the new revenue stream.
First-in-class FDA approval, projected multi‑billion‑dollar sales, and analyst support indicate a material positive catalyst.
Market effects
Strengthens the biotech/pharma sector outlook, especially companies developing antiviral therapies.
U.S. market may see a modest boost in healthcare stocks; UK market (GSK's primary listing) could also react positively.
Sets a precedent for functional cures in hepatitis B, potentially influencing global drug pipelines.
Counterpoint
Boxed warnings on liver toxicity and thrombocytopenia could limit adoption and dampen upside.
Key entities
- CompanyGSK
Pharmaceutical company receiving FDA approval for Hibsago.
- ProductHibsago (bepirovirsen)
First FDA‑approved antisense oligonucleotide for chronic hepatitis B.
